---
title: "INVO Fertility Stock Surges Following Q2 Earnings Beat"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296140168.md"
description: "INVO Fertility (NASDAQ: IVF) shares surged over 53% on Monday after reporting Q2 earnings that significantly beat Wall Street expectations. The company posted diluted EPS of $0.35, compared to an estimated loss of $0.65, driven by a $2.5 million remeasurement gain from its Birmingham clinic acquisition. While total revenue grew 17% to $2.18 million, slightly missing consensus estimates, consolidated clinic revenue expanded 18%. CEO Steve Shum highlighted strong operating momentum and plans for organic growth and disciplined acquisitions."
datetime: "2026-08-17T19:30:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296140168.md)
  - [en](https://longbridge.com/en/news/296140168.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296140168.md)
generator: "portal-rs"
---

# INVO Fertility Stock Surges Following Q2 Earnings Beat

Shares of **INVO Fertility Inc**. (NASDAQ:IVF) are surging Monday afternoon after the healthcare fertility company reported second-quarter financial results that significantly outperformed Wall Street expectations on bottom-line earnings.

-   INVO Fertility stock is charging ahead with explosive momentum. Why is IVF stock up today?

## **Key Second-Quarter Financial Results**

For the second quarter ended June 30, INVO Fertility posted diluted earnings per share of 35 cents, beating analyst estimates of a 65 cent loss per share. Quarterly net income reached $0.89 million, driven in part by an approximate $2.5 million remeasurement gain regarding its Birmingham, Alabama clinic acquisition. 

Total revenue grew 17% year-over-year to $2.18 million, slightly below consensus estimates of $2.71 million. Consolidated clinic revenue expanded 18% to $2.17 million, while clinic-level Adjusted EBITDA doubled sequentially to approximately $333,000.

## **Executive Commentary on Growth Strategy**

CEO **Steve Shum** highlighted the company’s operating momentum and business model validation. “Revenue increased 17% supported by the first full-quarter contribution from Family Beginnings and continued growth initiatives across our clinic network. Just as importantly, the clinic platform remained profitable on an Adjusted EBITDA basis before corporate operating and public company expenses,” Shum noted. 

He added that INVO intends to drive organic growth, leverage corporate infrastructure across a broader revenue base and pursue disciplined acquisitions of established, profitable fertility practices.

## IVF Shares Surge Monday Afternoon

**IVF Price Action:** INVO Fertility shares were up 53.52% at $1.49 at the time of publication on Monday, according to Benzinga Pro data.

 **Read Also: What's Going On With Amazon Stock Monday?** 

*Image: Shutterstock*

### Related Stocks

- [IVF.US](https://longbridge.com/en/quote/IVF.US.md)
- [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md)

## Related News & Research

- [INVO Fertility Gains Full Control of Alabama Clinic](https://longbridge.com/en/news/290882136.md)
- [INVO Fertility Q1 revenue jumps on clinic growth, acquisition](https://longbridge.com/en/news/290441756.md)
- [Workday stock is downgraded after buyout report as growth expectations are 'too optimistic'](https://longbridge.com/en/news/296104750.md)
- [Where will Workday stock be in 5 years if Silver Lake doesn't buy it?](https://longbridge.com/en/news/296091172.md)
- [Invo Fertility highlights retrospective IVF platelet-rich plasma studies at Midwest Reproductive Symposium 2026](https://longbridge.com/en/news/296495699.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**